May 2025, Vol 2, No 5

FDA officials recently approved durvalumab (Imfinzi; AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle-invasive bladder cancer. Read More ›

Officials with the FDA recently issued a communication in an attempt to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Read More ›

Expectant and new mothers who have TRICARE both in the United States, and now abroad, have more options thanks to an expansion of the program’s Childbirth and Breastfeeding Support Demonstration (CBSD) arm. Read More ›

A prepared statement issued by TRICARE Communications encouraged beneficiaries to avail themselves of virtual health options. Read More ›

Officials with the Department of Veterans Affairs (VA) have announced that they are vetting candidates to lead the Veterans Health and Veterans Benefits Administrations, and that VA Deputy Secretary Paul R. Lawrence, PhD, will chair both commissions. Read More ›

After more than a decade of providing treatment for gender dysphoria, officials with the Department of Veterans Affairs (VA) announced in March they will no longer be offering those treatments. Read More ›